Last reviewed · How we verify
MP0533 with Obinutuzumab pretreatment — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MP0533 with Obinutuzumab pretreatment (MP0533 with Obinutuzumab pretreatment) — Molecular Partners AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MP0533 with Obinutuzumab pretreatment TARGET | MP0533 with Obinutuzumab pretreatment | Molecular Partners AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MP0533 with Obinutuzumab pretreatment CI watch — RSS
- MP0533 with Obinutuzumab pretreatment CI watch — Atom
- MP0533 with Obinutuzumab pretreatment CI watch — JSON
- MP0533 with Obinutuzumab pretreatment alone — RSS
Cite this brief
Drug Landscape (2026). MP0533 with Obinutuzumab pretreatment — Competitive Intelligence Brief. https://druglandscape.com/ci/mp0533-with-obinutuzumab-pretreatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab